ArticleFuture oncology (London, England)2024

Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL).

Alessandro Troiani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.